Legislators hear wide-ranging views on 340B transparency as ND study begins

The North Dakota Legislative Interim Committee on Health Care spent Aug. 4 taking testimony on whether the state should require reporting by entities that participate in the federal 340B drug-discount program, with hospitals and clinics calling 340B a "lifeline" for rural services and insurers saying a lack of state-level data shifts costs to employers and members.